Table 1

Summary of clinical efficacy scores from trials evaluating abatacept

ACR20 (%)

ACR50 (%)

ACR70 (%)

DAS28 LDAS (%)

DAS28 remission (%)






Trial authors

Study phase

Study cohort

n

Duration

Background therapy

A

P

A

P

A

P

A

P

A

P


Moreland et al. [19]

II

DMARD failure

214

3 months

None

53%

31%

Kremer et al. [20]

II

MTX failure

339

6 months

MTX

60%

35.3%

36.5%

11.8%

16.5%

1.7%

Kremer et al. [21]

II

MTX failure

339

1 year

MTX

62.6%

36.1%

41.7%

20.2%

20.9%

7.6%

49.6%

21.9%

34.8%

10.1%

Kremer et al. [22]

III (AIM)

MTX failure

652

1 year

MTX

73.1%

39.7%

48.3%

18.2%

28.8%

6.1%

42.5%

9.9%

23.8%

1.9%

Genovese et al. [29]

III (ATTAIN)

TNF-α antagonist Failure

391

6 months

MTX, other DMARD

50.4%

19.5%

20.3%

3.8%

10.2%

1.5%

17.1%

3.1%

10%

0.8%

Schiff et al. [28]

III (ATTEST)

MTX failure: abatacept (A) or infliximab (I) active arms

431

6 months

MTX

A: 66.7%

41.8%

A: 40.4%

20%

A: 20.5%

9.1%

A: 20.7%

10.8%

A: 11.3%

2.9%

I: 59.4%

I: 37%

I: 24.2%

I: 25.6%

I: 12.8%

1 year

MTX

A: 72.4%

A: 45.5%

A: 26.3%

A: 35.3%

A: 18.7%

I: 55.8%

I: 36.4%

I: 20.6%

I: 22.4%

I: 12.2%


For abatacept (A), only responses for 10 mg/kg are included. ACR20/50/70, at least 20%/50%/70% improvement in the American College of Rheumatology criteria for rheumatoid arthritis; AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders; ATTEST, Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA; DAS28, Disease Activity Score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; LDAS, low disease activity scores; LTE, long-term extension; MTX, methotrexate; P, placebo; TNF, tumor necrosis factor.

Buch et al. Arthritis Research & Therapy 2008 10(Suppl 1):S5   doi:10.1186/ar2416